Argos Therapeutics, Inc. (ARGS) Sees Unusually-High Trading Volume

Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) saw unusually-high trading volume on Monday . Approximately 4,373,300 shares changed hands during mid-day trading, an increase of 128% from the previous session’s volume of 1,920,119 shares.The stock last traded at $0.17 and had previously closed at $0.19.

Separately, Zacks Investment Research lowered shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating and three have assigned a hold rating to the stock. Argos Therapeutics has an average rating of “Hold” and a consensus price target of $4.13.

The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new stake in Argos Therapeutics, Inc. (NASDAQ:ARGS) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics at the end of the most recent quarter. 28.22% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply